Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response observed in adenocarcinoma.

被引：0
|
作者：
Ilson, D. [1 ]
Shah, M. A. [1 ]
Kelsen, D. P. [1 ]
Janjigian, Y. Y. [1 ]
Tang, L. H. [1 ]
Campbell, J. [1 ]
Fuqua, L. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e14668
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14668
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II trial of postoperative concurrent chemoradiotherapy (CCRT) for poor-prognosis cancer of the esophagus and gastroesophageal junction (GEJ)
    Adelstein, D. J.
    Rice, T. W.
    Rybicki, L. A.
    Saxton, J. P.
    Videtic, G. M.
    Murthy, S. C.
    Mason, D. P.
    Rodriguez, C. P.
    Ives, D. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] A retrospective analysis of the role of gefitinib in the definitive management of esophageal/gastroesophageal junction (E/GEJ) cancer.
    Sohal, Davendra
    Rice, Thomas W.
    Rybicki, Lisa A.
    Rodriguez, Cristina P.
    Videtic, Gregory M. M.
    Saxton, Jerrold P.
    Murthy, Sudish C.
    Mason, David P.
    Phillips, Brooke Elizabeth
    Tubbs, Raymond R.
    Plesec, Thomas
    McNamara, Michael J.
    Ives, Denise I.
    Bodmann, Joanna
    Adelstein, David J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Survival outcomes for de novo versus relapsed stage IV gastric and gastroesophageal junction (GEJ) adenocarcinoma.
    Chan, Bryan Anthony
    Sim, Hao-Wen
    Natori, Akina
    Moignard, Stephanie
    Yokom, Daniel
    Lim, Charles Henry
    Jiang, Di Maria
    Chen, Eric Xueyu
    Knox, Jennifer J.
    Liu, Geoffrey
    Darling, Gail Elizabeth
    Swallow, Carol Jane
    Brar, Savtaj Singh
    Brierley, James D.
    Ringash, Jolie
    Wong, Rebecca
    Kim, John
    Hafezi-Bakhtiari, Sara
    Elimova, Elena
    Jang, Raymond Woo-Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [24] Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction
    Richards, D.
    McCollum, D.
    Wilfong, L.
    Sborov, M.
    Boehm, K. A.
    Zhan, F.
    Asmar, L.
    ANNALS OF ONCOLOGY, 2008, 19 (01) : 104 - 108
  • [25] A phase II study of perioperative mFOLFOX chemotherapy plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ), and stomach
    Sun, Weijing
    Saeed, Anwaar
    Al-Rajabi, Raed Moh'd Taiseer
    Kasi, Anup
    Veeramachaneni, Nirmal K.
    Al-Kasspooles, Mazin Mazin
    Baranda, Joaquina Celebre
    Phadnis, Milind
    Godwin, Andrew K.
    Olyaee, Mojtaba
    Madan, Rashna
    Nagji, Alykhan
    Williamson, Stephen K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [26] Paratracheal lymph node metastasis in operable localized esophageal and gastroesophageal junction adenocarcinoma.
    Harada, Kazuto
    Hwang, Hyunsoo
    Wang, Xuemei
    Abdelhakeem, Ahmed
    Iwatsuki, Masaaki
    Murphy, Mariela A. Blum
    Maru, Dipen M.
    Weston, Brian
    Lee, Jeffrey H.
    Rogers, Jane E.
    Thomas, Irene
    Shanbhag, Namita
    Bhutani, Manoop S.
    Quynh Nguyen
    Ikoma, Naruhiko
    Badgwell, Brian D.
    Hofstetter, Wayne Lewis
    Baba, Hideo
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] A phase II study of perioperative mFOLFOX plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ) and stomach.
    Sun, Weijing
    Saeed, Anwaar
    Mohd, Raed
    Al-Rajabi, Taiseer
    Kasi, Anup
    Veeramachaneni, Nirmal K.
    Al-Kasspooles, Mazin Francis
    Baranda, Joaquina Celebre
    Phadnis, Milind A.
    Godwin, Andrew K.
    Olyaee, Mojtaba
    Madan, Rashna
    Streeter, Natalie
    Nagji, Alykhan
    Williamson, Stephen K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma.
    Kunz, Pamela L.
    Nandoskar, Prachi
    Koontz, Michael Zach
    Ji, Hanlee
    Ford, James M.
    Balise, Raymond R.
    Kamaya, Aya
    Rubin, Daniel
    Fisher, George A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [29] A phase II trial of the Src kinase inhibitor AZD0530 in patients with metastatic or locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A trial of the PMH phase II consortium
    Mackay, H.
    Au, H.
    McWhirter, E.
    Alcindor, T.
    Jarvi, A.
    MacAlpine, K.
    Wang, L.
    Wright, J. J.
    Oza, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Epirubicin, oxaliplatin, and docetaxel (EOD) combination in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A phase II study
    Di Lauro, L.
    Giacinti, L.
    Arena, M. G.
    Fattoruso, S. I.
    Foggi, P.
    Lopez, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345